INC Research‘s Kendle acquisition vaulted the North Carolina clinical research organization into the CRO industry’s top five and according to CEO James Ogle, helps the company become a global player.
Ogle spoke with Outsourcing Pharma, a British publication that covers the CRO industry. Audio of the Outsourcing Pharma interview can be heard here. In the interview, Ogle explains that the deal, first announced in April, helped expand the Raleigh-based CRO’s geographic reach and also reinforce its capabilities in the top areas for drug development.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
INC Research late last month closed on its $232 million acquisition of Cincinnati, Ohio-based CRO Kendle. At the beginning of June, INC Research acquired Australia CRO Trident Clinical Research.
Ogle tells Outsourcing Pharma that Kendle brings INC Research a strong presence in Latin America and Asia while Trident brings to the company additional geographic breadth.
Ogle said that INC Research currently doesn’t have any plans for further acquisitions “in the near future.” But he leaves the door open for future acquisitions that bring the company a geographic or therapeutic capability it doesn’t currently have.
“One should never say never,” Ogle said.
